职称：

教授

研究方向：

重大呼吸系统感染和肺损伤

研究工作：

研究领域包括肺感染与免疫、脓毒症、呼吸机相关肺损伤和干细胞治疗等，其中，转化医学研究重点为急性肺损伤和脓毒症的发病机制和治疗策略。在宿主免疫防御、急性呼吸窘迫综合症及脓毒症方面揭示了关键病理内在机制及相关临床应用。

科研项目：

1、COVID-19 Rapid response funding grant supplement, Sex as a biological variant in COVID-19，Canadian Institutes of Health Research，2020年5月-2021年3月，78.488万元；

2、Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)，Canadian Institutes of Health Research，2020年2月-2022年2月，808.88万元；

3、Mechanisms and Therapies of ARDS，Canadian Institutes of Health Research，2015-2023年，1354.6万元；

4、4.Aiming at a new target in endotoxin-associated lung damage: The Ig domain 3 of ICAM-1，Unity Health Toronto，2023年10月-2028年9月，532.1万元；

5、5.道及肺损伤的干细胞治疗策略与作用机制，广州再生医学与健康广东省实验室，2019年3月-2022年2月，300万元。

代表性学术论文：

1、Li Y, Jerkic M, Slutsky AS, Zhang H. Molecular mechanisms of sex bias differences in COVID-19 mortality. Crit Care. 2020 Jul 9;24(1):405. doi: 10.1186/s13054-020-03118-8. PMID: 32646459；PMCID: PMC7347256.

2、Wu J, Han B, Fanelli V, Wen X, Huang Y, Luo A, Ghazarian M, Wang D, Khang J, Morriello F, Liaw PC, Marshall J, Zhong N, Guan X, Slutsky AS, Li Y, Zhang H. Distinctive Roles and Mechanisms of Human Neutrophil Peptides in Experimental Sepsis and Acute Respiratory Distress Syndrome. Crit Care Med. 2018 Sep;46(9):e921-e927. doi: 10.1097/CCM.0000000000003265. PMID: 29979223.

3、Onodera Y, Liang J, Li Y, Griffin B, Thanabalasingam T, Lu C, Zhu J, Liu M, Moraes T, Zheng W, Khateeb J, Khang J, Huang Y, Jerkic M, Nakane M, Baker A, Orser B, Chen YW, Wirnsberger G, Penninger JM, Rotstein OD, Slutsky AS, Li Y, Mubareka S, Zhang H. Inhalation of ACE2 as a therapeutic target on sex-bias differences in SARS-CoV-2 infection and variant of concern. iScience. 2023 Jul 25;26(8):107470. doi: 10.1016/j.isci.2023.107470. PMID: 37609639; PMCID: PMC10440513.

4、Zhang H, Li Y, Slutsky AS. Precision medicine for cell therapy in acute respiratory distress syndrome. Lancet Respir Med. 2019 Apr;7(4):e13. doi: 10.1016/S2213-2600(19)30089-X. PMID: 30926050.

5、Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3. PMID: 32125455; PMCID: PMC7079879.

6、Islam D, Huang Y, Fanelli V, Delsedime L, Wu S, Khang J, Han B, Grassi A, Li M, Xu Y, Luo A, Wu J, Liu X, McKillop M, Medin J, Qiu H, Zhong N, Liu M, Laffey J, Li Y, Zhang H. Identification and Modulation of Microenvironment Is Crucial for Effective Mesenchymal Stromal Cell Therapy in Acute Lung Injury. Am J Respir Crit Care Med. 2019 May 15;199(10):1214-1224. doi: 10.1164/rccm.201802-0356OC. PMID: 30521764.

7、Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care. 2021 Jul 12;25(1):244. doi: 10.1186/s13054-021-03662-x. PMID: 34253247; PMCID: PMC8274962.

8、Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, Grieb A, Pawelka E, Laferl H, Wenisch C, Neuhold S, Haider D, Stiasny K, Bergthaler A, Puchhammer-Stoeckl E, Mirazimi A, Montserrat N, Zhang H, Slutsky AS, Penninger JM. Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020 Nov;8(11):1154-1158. doi: 10.1016/S2213-2600(20)30418-5. Epub 2020 Sep 24. Erratum in: Lancet Respir Med. 2020 Nov;8(11):e78. PMID: 33131609; PMCID: PMC7515587.

联系方式：

Email: Haibo.Zhang@unityhealth.to